have presented data of a Phase II study in which HPV-related SCCHN were treated with induction chemotherapy docetaxel, cisplatin and 5-fluorouracil (TPF) followed by a de-escalated chemoradiation regimen consisting of a total of 50 Gy associated with the anti-EGFR monoclonal antibody cetuximab. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.